The EVOLVESM Workflow, for chronic back and leg pain patients, offers standardised guidance to optimise patient therapy with HD and LD dosing options.

Download the prospective evidence


You’ve asked for standardised guidance for trialling of spinal cord stimulation.  The EvolveSM Workflow balances the simplicity found in the latest understanding of High Dose  stimulation, without sacrificing the versatility of 40+ years of Low Dose stimulation. To make real progress in spinal cord stimulation, simplicity, and versatility must work together.



Historically, the industry’s approach to spinal cord stimulation has been to add device features in an effort to optimise patient treatment.

However, this has resulted in therapy complexity and an exhausting number of choices in treating the subject of pain.


Recently, products have focused on simplicity, resulting in a more consistent approach.

But this consistency has its limitations in support of individual patient optimisation over time.


Pain is personal. Therapy must be versatile to treat the broadest range of patients. The smarter way forward is a balanced approach, providing simplicity through therapy standardisation.


A workflow is guidance only. Physicians should use their medical judgment and product labelling to optimise therapy for individual patients, which may require discontinuation or modification of a workflow. 

Prospective EVIDENCE - The VECTORS Study

VECTORS is a prospective, multicentre, single-arm, nonrandomised study of targeted stimulation parameters in SCS designed to evaluate the long-term efficacy of the therapy when the EvolveSM workflow is used.  VECTORS is a Medtronic-Sponsored Study. 

The VECTORS study measures improvement in pain scores as the Verdolin data does, but adds in patient satisfaction and goal setting – key parts of the Evolve workflow

After the real-world results from the retrospective, multi-centre cohort study by Verdolin, the VECTORS study is our flagship commitment in continuing to build a higher level of evidence for the EvolveSM workflow and the ability to offer patients both High Dose and Low Dose stimulation.

Retrospective EVIDENCE- Verdolin

In a recent multi-centre study of 114 patients, during the trial, 83% were responders
( ≥50% pain relief) with an average pain reduction of 75%


In the 3+ month follow up cohort (n=39), the average reduction in pain was 65% and, 87% of patients were still using just HD stimulation



Image of a young family walking in fields with grandparents

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at

For applicable products, consult instructions for use on Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.